SrasV1, Ncbi, Merge, bibRecord, 003060

Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.

Identifieur interne : 003060 ( Ncbi/Merge ); précédent : 003059; suivant : 003061

Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.

Auteurs : David M. Loczenski-Brown [Royaume-Uni] ; Sarah Jones [Royaume-Uni] ; Jeni Luckett [Royaume-Uni] ; Zoe Daniel [Royaume-Uni] ; Madelaine C. Brearley [Royaume-Uni] ; Francis J P. Ebling [Royaume-Uni] ; Tim Parr [Royaume-Uni] ; John M. Brameld [Royaume-Uni]

Source :

PloS one [ 1932-6203 ] ; 2019.

RBID : pubmed:31237922

Descripteurs français

English descriptors

KwdEn :
- Adrenergic beta-Agonists (pharmacology), Animals, Clenbuterol (pharmacology), Dependovirus (metabolism), Male, Mice, Mice, Inbred C57BL, Muscle Development (drug effects), Muscle Fibers, Skeletal (drug effects), Muscle Fibers, Skeletal (metabolism), Myosin Heavy Chains (drug effects), Myosin Heavy Chains (metabolism), Phenethylamines (pharmacology), Phosphoenolpyruvate Carboxykinase (ATP) (metabolism), Protein Isoforms (metabolism).
MESH :
- chemical , drug effects : Myosin Heavy Chains.
- chemical , metabolism : Myosin Heavy Chains, Phosphoenolpyruvate Carboxykinase (ATP), Protein Isoforms.
- chemical , pharmacology : Adrenergic beta-Agonists, Clenbuterol, Phenethylamines.
- drug effects : Muscle Development, Muscle Fibers, Skeletal.
- metabolism : Dependovirus, Muscle Fibers, Skeletal.
- Animals, Male, Mice, Mice, Inbred C57BL.

Abstract

We previously identified PEPCK-M (encoded by the Pck2 gene) to be highly up-regulated in skeletal muscle of pigs treated with Ractopamine, an anabolic beta-adrenergic receptor agonist. To determine whether PEPCK-M had a causative role in modulating the skeletal muscle growth response to Ractopamine, we used adeno-associated virus 1 (AAV1) to over-express Pck2 (AAV-Pck2) in murine skeletal muscle. A contralateral limb design was employed, such that each mouse served as its own control (injected with a GFP-only expressing AAV1, labelled AAV-GFP). Daily injections of Clenbuterol (1 mg/kg for 21 days) or vehicle control were also carried out to assess the effects of AAV-Pck2 overexpression on the anabolic response to a beta-adrenergic agonist. AAV-Pck2 overexpression in leg muscles of male C57BL6/J mice for 4 weeks (6-10 weeks of age) increased Pck2 mRNA (~100-fold), protein (not quantifiable) and enzyme activity (~3-fold). There was a trend (p = 0.0798) for AAV-Pck2 overexpression to reduce TA muscle weights, but there was no significant effect on muscle fibre diameters or myosin heavy chain isoform (MyHC) mRNA expression. When skeletal muscle growth was induced by daily administration of Clenbuterol (for 21 days), overexpression of AAV-Pck2 had no effect on the growth response, nor did it alter the expression of Phosphoserine Aminotransferase-1 (Psat1) or Asparagine Synthetase (Asns) mRNA or the Clenbuterol-induced decreases in MyHC IIa and IIx mRNA expression (p = 0.0065 and p = 0.0267 respectively). However AAV-Pck2 overexpression reduced TA muscle weights (p = 0.0434), particularly in the Control (vehicle treated) mice (p = 0.059 for AAV x Clenbuterol interaction) and increased the expression of Seryl-tRNA Synthetase (Sars) mRNA (p = 0.0477). Hence, contrary to the original hypothesis, AAV-Pck2 overexpression reduced TA muscle weights and did not mimic or alter the muscle hypertrophic effects of the beta-adrenergic agonist, Clenbuterol.

DOI: 10.1371/journal.pone.0218970
PubMed: 31237922

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000892
to stream PubMed, to step Curation: 000892
to stream PubMed, to step Checkpoint: 000906

Links to Exploration step

pubmed:31237922

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.</title>
<author><name sortKey="Loczenski Brown, David M" sort="Loczenski Brown, David M" uniqKey="Loczenski Brown D" first="David M" last="Loczenski-Brown">David M. Loczenski-Brown</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jones, Sarah" sort="Jones, Sarah" uniqKey="Jones S" first="Sarah" last="Jones">Sarah Jones</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luckett, Jeni" sort="Luckett, Jeni" uniqKey="Luckett J" first="Jeni" last="Luckett">Jeni Luckett</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, University of Nottingham Medical School, Nottingham, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Medicine, University of Nottingham Medical School, Nottingham</wicri:regionArea>
<wicri:noRegion>Nottingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Daniel, Zoe" sort="Daniel, Zoe" uniqKey="Daniel Z" first="Zoe" last="Daniel">Zoe Daniel</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brearley, Madelaine C" sort="Brearley, Madelaine C" uniqKey="Brearley M" first="Madelaine C" last="Brearley">Madelaine C. Brearley</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ebling, Francis J P" sort="Ebling, Francis J P" uniqKey="Ebling F" first="Francis J P" last="Ebling">Francis J P. Ebling</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Life Sciences, University of Nottingham Medical School, Nottingham</wicri:regionArea>
<wicri:noRegion>Nottingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Parr, Tim" sort="Parr, Tim" uniqKey="Parr T" first="Tim" last="Parr">Tim Parr</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brameld, John M" sort="Brameld, John M" uniqKey="Brameld J" first="John M" last="Brameld">John M. Brameld</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31237922</idno>
<idno type="pmid">31237922</idno>
<idno type="doi">10.1371/journal.pone.0218970</idno>
<idno type="wicri:Area/PubMed/Corpus">000892</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000892</idno>
<idno type="wicri:Area/PubMed/Curation">000892</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000892</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000906</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000906</idno>
<idno type="wicri:Area/Ncbi/Merge">003060</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.</title>
<author><name sortKey="Loczenski Brown, David M" sort="Loczenski Brown, David M" uniqKey="Loczenski Brown D" first="David M" last="Loczenski-Brown">David M. Loczenski-Brown</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jones, Sarah" sort="Jones, Sarah" uniqKey="Jones S" first="Sarah" last="Jones">Sarah Jones</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luckett, Jeni" sort="Luckett, Jeni" uniqKey="Luckett J" first="Jeni" last="Luckett">Jeni Luckett</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, University of Nottingham Medical School, Nottingham, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Medicine, University of Nottingham Medical School, Nottingham</wicri:regionArea>
<wicri:noRegion>Nottingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Daniel, Zoe" sort="Daniel, Zoe" uniqKey="Daniel Z" first="Zoe" last="Daniel">Zoe Daniel</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brearley, Madelaine C" sort="Brearley, Madelaine C" uniqKey="Brearley M" first="Madelaine C" last="Brearley">Madelaine C. Brearley</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ebling, Francis J P" sort="Ebling, Francis J P" uniqKey="Ebling F" first="Francis J P" last="Ebling">Francis J P. Ebling</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Life Sciences, University of Nottingham Medical School, Nottingham</wicri:regionArea>
<wicri:noRegion>Nottingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Parr, Tim" sort="Parr, Tim" uniqKey="Parr T" first="Tim" last="Parr">Tim Parr</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brameld, John M" sort="Brameld, John M" uniqKey="Brameld J" first="John M" last="Brameld">John M. Brameld</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough</wicri:regionArea>
<orgName type="university">Université de Nottingham</orgName>
<placeName><settlement type="city">Nottingham</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Nottinghamshire</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Agonists (pharmacology)</term>
<term>Animals</term>
<term>Clenbuterol (pharmacology)</term>
<term>Dependovirus (metabolism)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Muscle Development (drug effects)</term>
<term>Muscle Fibers, Skeletal (drug effects)</term>
<term>Muscle Fibers, Skeletal (metabolism)</term>
<term>Myosin Heavy Chains (drug effects)</term>
<term>Myosin Heavy Chains (metabolism)</term>
<term>Phenethylamines (pharmacology)</term>
<term>Phosphoenolpyruvate Carboxykinase (ATP) (metabolism)</term>
<term>Protein Isoforms (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agonistes bêta-adrénergiques (pharmacologie)</term>
<term>Animaux</term>
<term>Chaînes lourdes de myosine ()</term>
<term>Chaînes lourdes de myosine (métabolisme)</term>
<term>Clenbutérol (pharmacologie)</term>
<term>Dependovirus (métabolisme)</term>
<term>Développement musculaire ()</term>
<term>Fibres musculaires squelettiques ()</term>
<term>Fibres musculaires squelettiques (métabolisme)</term>
<term>Isoformes de protéines (métabolisme)</term>
<term>Mâle</term>
<term>Phosphoenolpyruvate carboxykinase (ATP) (métabolisme)</term>
<term>Phénéthylamines (pharmacologie)</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Myosin Heavy Chains</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Myosin Heavy Chains</term>
<term>Phosphoenolpyruvate Carboxykinase (ATP)</term>
<term>Protein Isoforms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic beta-Agonists</term>
<term>Clenbuterol</term>
<term>Phenethylamines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Muscle Development</term>
<term>Muscle Fibers, Skeletal</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dependovirus</term>
<term>Muscle Fibers, Skeletal</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Chaînes lourdes de myosine</term>
<term>Dependovirus</term>
<term>Fibres musculaires squelettiques</term>
<term>Isoformes de protéines</term>
<term>Phosphoenolpyruvate carboxykinase (ATP)</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agonistes bêta-adrénergiques</term>
<term>Clenbutérol</term>
<term>Phénéthylamines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Chaînes lourdes de myosine</term>
<term>Développement musculaire</term>
<term>Fibres musculaires squelettiques</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We previously identified PEPCK-M (encoded by the Pck2 gene) to be highly up-regulated in skeletal muscle of pigs treated with Ractopamine, an anabolic beta-adrenergic receptor agonist. To determine whether PEPCK-M had a causative role in modulating the skeletal muscle growth response to Ractopamine, we used adeno-associated virus 1 (AAV1) to over-express Pck2 (AAV-Pck2) in murine skeletal muscle. A contralateral limb design was employed, such that each mouse served as its own control (injected with a GFP-only expressing AAV1, labelled AAV-GFP). Daily injections of Clenbuterol (1 mg/kg for 21 days) or vehicle control were also carried out to assess the effects of AAV-Pck2 overexpression on the anabolic response to a beta-adrenergic agonist. AAV-Pck2 overexpression in leg muscles of male C57BL6/J mice for 4 weeks (6-10 weeks of age) increased Pck2 mRNA (~100-fold), protein (not quantifiable) and enzyme activity (~3-fold). There was a trend (p = 0.0798) for AAV-Pck2 overexpression to reduce TA muscle weights, but there was no significant effect on muscle fibre diameters or myosin heavy chain isoform (MyHC) mRNA expression. When skeletal muscle growth was induced by daily administration of Clenbuterol (for 21 days), overexpression of AAV-Pck2 had no effect on the growth response, nor did it alter the expression of Phosphoserine Aminotransferase-1 (Psat1) or Asparagine Synthetase (Asns) mRNA or the Clenbuterol-induced decreases in MyHC IIa and IIx mRNA expression (p = 0.0065 and p = 0.0267 respectively). However AAV-Pck2 overexpression reduced TA muscle weights (p = 0.0434), particularly in the Control (vehicle treated) mice (p = 0.059 for AAV x Clenbuterol interaction) and increased the expression of Seryl-tRNA Synthetase (Sars) mRNA (p = 0.0477). Hence, contrary to the original hypothesis, AAV-Pck2 overexpression reduced TA muscle weights and did not mimic or alter the muscle hypertrophic effects of the beta-adrenergic agonist, Clenbuterol.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31237922</PMID>
<DateCompleted><Year>2020</Year>
<Month>02</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>6</Issue>
<PubDate><Year>2019</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.</ArticleTitle>
<Pagination><MedlinePgn>e0218970</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0218970</ELocationID>
<Abstract><AbstractText>We previously identified PEPCK-M (encoded by the Pck2 gene) to be highly up-regulated in skeletal muscle of pigs treated with Ractopamine, an anabolic beta-adrenergic receptor agonist. To determine whether PEPCK-M had a causative role in modulating the skeletal muscle growth response to Ractopamine, we used adeno-associated virus 1 (AAV1) to over-express Pck2 (AAV-Pck2) in murine skeletal muscle. A contralateral limb design was employed, such that each mouse served as its own control (injected with a GFP-only expressing AAV1, labelled AAV-GFP). Daily injections of Clenbuterol (1 mg/kg for 21 days) or vehicle control were also carried out to assess the effects of AAV-Pck2 overexpression on the anabolic response to a beta-adrenergic agonist. AAV-Pck2 overexpression in leg muscles of male C57BL6/J mice for 4 weeks (6-10 weeks of age) increased Pck2 mRNA (~100-fold), protein (not quantifiable) and enzyme activity (~3-fold). There was a trend (p = 0.0798) for AAV-Pck2 overexpression to reduce TA muscle weights, but there was no significant effect on muscle fibre diameters or myosin heavy chain isoform (MyHC) mRNA expression. When skeletal muscle growth was induced by daily administration of Clenbuterol (for 21 days), overexpression of AAV-Pck2 had no effect on the growth response, nor did it alter the expression of Phosphoserine Aminotransferase-1 (Psat1) or Asparagine Synthetase (Asns) mRNA or the Clenbuterol-induced decreases in MyHC IIa and IIx mRNA expression (p = 0.0065 and p = 0.0267 respectively). However AAV-Pck2 overexpression reduced TA muscle weights (p = 0.0434), particularly in the Control (vehicle treated) mice (p = 0.059 for AAV x Clenbuterol interaction) and increased the expression of Seryl-tRNA Synthetase (Sars) mRNA (p = 0.0477). Hence, contrary to the original hypothesis, AAV-Pck2 overexpression reduced TA muscle weights and did not mimic or alter the muscle hypertrophic effects of the beta-adrenergic agonist, Clenbuterol.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loczenski-Brown</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jones</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Luckett</LastName>
<ForeName>Jeni</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>School of Medicine, University of Nottingham Medical School, Nottingham, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Daniel</LastName>
<ForeName>Zoe</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brearley</LastName>
<ForeName>Madelaine C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ebling</LastName>
<ForeName>Francis J P</ForeName>
<Initials>FJP</Initials>
<AffiliationInfo><Affiliation>School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Parr</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brameld</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
<Identifier Source="ORCID">0000-0003-4942-080X</Identifier>
<AffiliationInfo><Affiliation>School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID> BB/MM001385/1</GrantID>
<Acronym>BB_</Acronym>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010627">Phenethylamines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>57370OZ3P1</RegistryNumber>
<NameOfSubstance UI="C060897">ractopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.4.1</RegistryNumber>
<NameOfSubstance UI="D018995">Myosin Heavy Chains</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 4.1.1.49</RegistryNumber>
<NameOfSubstance UI="C000611827">PEPCK-M protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 4.1.1.49</RegistryNumber>
<NameOfSubstance UI="D019764">Phosphoenolpyruvate Carboxykinase (ATP)</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>XTZ6AXU7KN</RegistryNumber>
<NameOfSubstance UI="D002976">Clenbuterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002976" MajorTopicYN="N">Clenbuterol</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024510" MajorTopicYN="N">Muscle Development</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018485" MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018995" MajorTopicYN="N">Myosin Heavy Chains</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010627" MajorTopicYN="N">Phenethylamines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019764" MajorTopicYN="N">Phosphoenolpyruvate Carboxykinase (ATP)</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>This research was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and Zoetis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have declared that no other competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>02</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>06</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>6</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>2</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31237922</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0218970</ArticleId>
<ArticleId IdType="pii">PONE-D-19-03500</ArticleId>
<ArticleId IdType="pmc">PMC6592604</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2009 Oct 2;284(40):27025-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19636077</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Neuromuscul Disord. 2004 Oct;14(10):675-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351425</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ageing Res Rev. 2015 Nov;24(Pt B):263-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26342566</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Meat Sci. 2016 Oct;120:93-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27179582</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2007 Nov 9;282(45):32844-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17716967</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2009 Sep 25;284(39):26578-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19635791</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Cell. 2015 Oct 15;60(2):195-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26474064</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Anim Sci. 2009 Dec;87(12):3915-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19684280</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2018 Jul 27;13(7):e0201481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30052661</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Animal. 2015 Feb;9(2):285-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25213627</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 Jun 28;6:28693</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27350173</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 1951 Nov;193(1):265-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14907713</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2018 Oct 29;8(1):15915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30374102</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Oncogene. 2015 Feb 19;34(8):1044-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24632615</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>BMC Biol. 2008 Sep 15;6:40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18793381</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Muscle Res Cell Motil. 2012 Mar;32(6):383-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22012579</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem J. 1998 Jul 15;333 ( Pt 2):359-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9657976</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2014 Aug 8;289(32):22090-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24973213</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Nottinghamshire</li>
</region>
<settlement><li>Nottingham</li>
</settlement>
<orgName><li>Université de Nottingham</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Loczenski Brown, David M" sort="Loczenski Brown, David M" uniqKey="Loczenski Brown D" first="David M" last="Loczenski-Brown">David M. Loczenski-Brown</name>
</region>
<name sortKey="Brameld, John M" sort="Brameld, John M" uniqKey="Brameld J" first="John M" last="Brameld">John M. Brameld</name>
<name sortKey="Brearley, Madelaine C" sort="Brearley, Madelaine C" uniqKey="Brearley M" first="Madelaine C" last="Brearley">Madelaine C. Brearley</name>
<name sortKey="Daniel, Zoe" sort="Daniel, Zoe" uniqKey="Daniel Z" first="Zoe" last="Daniel">Zoe Daniel</name>
<name sortKey="Ebling, Francis J P" sort="Ebling, Francis J P" uniqKey="Ebling F" first="Francis J P" last="Ebling">Francis J P. Ebling</name>
<name sortKey="Jones, Sarah" sort="Jones, Sarah" uniqKey="Jones S" first="Sarah" last="Jones">Sarah Jones</name>
<name sortKey="Luckett, Jeni" sort="Luckett, Jeni" uniqKey="Luckett J" first="Jeni" last="Luckett">Jeni Luckett</name>
<name sortKey="Parr, Tim" sort="Parr, Tim" uniqKey="Parr T" first="Tim" last="Parr">Tim Parr</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003060 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003060 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:31237922
   |texte=   Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:31237922" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.

Effect of adeno-associated virus (AAV)-mediated overexpression of PEPCK-M (Pck2) on Clenbuterol-induced muscle growth.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki